FSD Pharma IncNASDAQ:HUGENASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)View on Canadian Exchange
- LAST PRICE0.1439
- TODAY'S CHANGE (%)-0.0002 (-0.1388%)
- Bid / Lots0.1441/ 1
- Ask / Lots0.1475/ 36
- Open / Previous Close0.1440 / 0.1441
- Day Range
- 52 Week Range
- Volume150,850
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HUGE |
|---|---|---|
| 09:32 ET | 14996 | 0.14665 |
| 09:36 ET | 69192 | 0.1489 |
| 09:38 ET | 1250 | 0.1489 |
| 09:41 ET | 670 | 0.148 |
| 09:43 ET | 499 | 0.1421 |
| 09:45 ET | 100 | 0.148 |
| 09:50 ET | 7800 | 0.1428 |
| 09:52 ET | 500 | 0.147 |
| 09:54 ET | 3360 | 0.1469 |
| 09:59 ET | 19904 | 0.146 |
| 10:01 ET | 500 | 0.148 |
| 10:08 ET | 120 | 0.1434 |
| 10:12 ET | 2800 | 0.1454 |
| 10:14 ET | 2945 | 0.1439 |
Jul 4, 2024
FSD Pharma Files Amended and Restated Material Change Report, from 8:02AM ET on Thursday Jul 04, 2024 by Dow Jones
8:02AM ET on Thursday Jul 04, 2024 by Dow Jones
Jun 28, 2024
FSD Pharma provides Corporate Update, from 5:00PM ET on Friday Jun 28, 2024 by Dow Jones
5:00PM ET on Friday Jun 28, 2024 by Dow JonesFSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd., from 7:31AM ET on Friday Jun 28, 2024 by Dow Jones
7:31AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
FSD Pharma Inc | 10.1M | 0.0x | --- |
Company Information
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
Contact Information
- Headquarters
- 55 University Ave. , Suite 1003TORONTO, ON, Canada M5J 2H7
- Phone
- 416-854-8884
- Fax
- 416-854-8884
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 50.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
